Plain-English translation of NCT05271162 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Some cancer chemotherapy drugs, especially anthracyclines like doxorubicin, can damage the heart muscle and lead to heart failure—a serious side effect called cardiotoxicity. This trial is testing whether a medication called empagliflozin, taken once daily as a pill, can prevent this heart damage in patients who are about to receive high-dose anthracycline chemotherapy. Researchers want to know if this treatment can protect your heart while you're being treated for cancer.
Right now, doctors have very limited options to prevent heart damage from cancer chemotherapy. The only approved preventive medication is expensive and not recommended for all patients. This trial exists because there's an urgent need for a safe, effective way to protect patients' hearts during cancer treatment, and early research suggests this medication might help.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to take either the study medication or a placebo (a pill with no active drug) once daily by mouth. You will take your assigned pill throughout your cancer chemotherapy and for some time afterward. You'll have regular visits where doctors will check your heart health with blood tests and heart imaging scans. The study involves about 220 patients total, and researchers will compare heart health outcomes between those who received the medication and those who received placebo.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Poland